Skip to content
OpenCapital
Get started

Cytek Biosciences, Inc. CTKB Gain on investments, accretion, and amortization, net

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%—
Net margin-36.2%—
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%—
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept ctkb:LossGainOnInvestmentsAccretionAndAmortizationNet.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s gain on investments, accretion, and amortization, net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s gain on investments, accretion, and amortization, net?
Cytek Biosciences, Inc. (CTKB) reported gain on investments, accretion, and amortization, net of -$1.26M in Q1 2026.
How has Cytek Biosciences, Inc.'s gain on investments, accretion, and amortization, net changed year-over-year?
Cytek Biosciences, Inc.'s gain on investments, accretion, and amortization, net increased by 15.9% year-over-year, from -$1.49M to -$1.26M.